TAKEDA PHARMACEUTICAL CO TKPHF overview

EQS-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2023 (IFRS) 26-Oct-2023 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2021 (IFRS) 03-Feb-2022 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 04-Feb-2021 / 07:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 29-Oct-2020 / 07:01 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Disposal Takeda Pharmaceutical Company Limited: Takeda to Divest its Japan Consumer Health Care Business Unit to Blackstone for JPY 242.0 Billion 24-Aug-2020 / 09:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Takeda to Divest its Japan Consumer Health...

DGAP-Ad-hoc: Takeda Pharmaceutical Company Limited / Key word(s): Forecast Takeda Pharmaceutical Company Limited: Notice of the Revised Forecast of Consolidated Financials for FY2020 (IFRS) 31-Jul-2020 / 08:00 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. Notice of the Revised Forecast of Consolidated Financials for...

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced the completion of its previously-announced sale of a portfolio of select over-the-counter (OTC) and prescription pharmaceutical assets in a number of Near East, Middle East and Africa countries within its Growth and Emerging Markets Business Unit (GEM BU) to Acino for a total value in excess of $200 million USD. The divestment agreement was first announced in October 2019. The transaction includes...

Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it has entered into an agreement to divest a portfolio of select non-core products exclusively in Latin America to Hypera S.A. (“Hypera Pharma”), Brazil’s largest pharmaceutical company with a leading position in branded prescriptions, consumer health and branded generics, for a total value of $825M USD. The portfolio includes over-the-counter and prescription pharmaceutical products sold in...